No Detail Found!

Frequency of hepatitis-c reinfection after treatment with direct-acting antiviral therapy undergoing maintenance hemodialysis

Author(s)
Muhammad Ali Departments of Nephrology, Fazaia Ruth Pfau Medical College, Pakistan
Mahjabeen Yaseen Departments of Nephrology, Fazaia Ruth Pfau Medical College, Pakistan
Saba Aziz Jinnah postgraduate Medical Center, Karachi, Pakistan
Ayesha Aijaz Jinnah postgraduate Medical Center, Karachi, Pakistan
Abdul Manan Junejo Jinnah postgraduate Medical Center, Karachi, Pakistan
Hina Iram Jinnah postgraduate Medical Center, Karachi, Pakistan
Abstract
Objective: To assess the frequency of hepatitis-c reinfection after treatment with direct-acting antiviral (DAA) therapy undergoing maintenance hemodialysis. Methodology: This observational, cross-sectional study included 160 patients in the Department of Nephrology, JPMC, from November 2019 to October 2020. The sampling technique used was non-probability. Demographic information, such as age, gender, HCV genotype, HCV RNA, and comorbidities, was gathered from the medical data or by interviews with patients and amily members. Results: The severity of liver disease was classified according to the Child-Turcotte-Pugh (CTP) score. We found that 38.9% patients had an average score of 6, and 53.7% were classified in CTP class A. The re-infection rate of HCV was very low after treatment with DAA. Conclusion: DAAs have become a successful treat-ment for HCV, allowing the virus to be eradicated.
Publication Details
Page(s) 610-614
DOI DOI not available
Published Journal: Rawal Medical Journal, Volume: 50, Issue: 3, Year: 2025

Request the full text from PASTIC

Keywords
Hemodialysis, Hepatitis C virus (HCV), direct-acting antivirals (DAAs).
References
Jadoul M,Bieber BA,Martin P,Akiba T,Nwankwo C,Arduino JM .2019 .Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney Int, 95 : 939-47.
Annex W. .2021 .Global progress report on HIV, viral hepatitis, and sexually transmitted infections. , : .
Organization WH . .. Global hepatitis report 2017., : .
Toyoda H,Kikuchi K. .2023 .Management of dialysis patients with hepatitis C virus in the era of direct‐acting antiviral therapy. Ther Apher Dial, 27 : 831-8.
Yu ML,Huang CF,Wei YJ,Lin WY,Lin YH,Hsu PY .2021 .Establishment of an outreach, grouping healthcare system to achieve micro elimination of HCV for uremic patients in haemodialysis centres (ERASE-C). Gut, 70 : 2349-58.
Hu TH,Su WW,Yang CC,Yang CC,Kuo WH,Chen YY .2021 .Elimination of hepatitis C virus in a dialysis population: a collaborative care model in Taiwan. AJKD, 78 : 511-9.
Huang CF,Chen GJ,Hung CC,Yu ML .2023 .HCV Micro elimination for High-risk Special Populations. J Infect Dis, 228 : 168-79.
Maruyama A,Partovi N,Yoshida EM,Erb SR,Azalgara VM,Hussaini T. .2017 .A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease. Nephrol Dial Transpl, 32 : 35-41.
Cheema SS,Tauseef A,Fatima M,Iqbal MD,Khurshid S.,One Year Mortality .2023 .Reinfection Rate of Hepatitis C Among Patients on Hemodialysis after Successful DirectActing Antiviral Treatment. Medical Forum Monthly, 34 : 107-11.
Liu CH,Peng CY,Kao WY,Yang SS,Shih YL,Lin CL .2022 .Hepatitis C virus reinfection in patients on hemodialysis after achieving sustained virologic response with antiviral treatment. Alim Pharmacol Therap, 55 : 434-45.
Marc L,Mihaescu A,Lupusoru R,Schiller O,Bob F,Chisavu L .2023 .Hepatitis C and hepatitis B virus infection in hemodialysis patients after nationwide direct antiviral agents therapy-experience of 10 Romanian HD centers. Int Urol Nephrol, 55 : 2951-8.
Kashani M,Karimi M,Sharifi Rayeni A,Azizi Nadian MA,Mortezazadeh M,Parsaei A,Abolghasemi N .2024 .Efficacy of Direct Acting Antivirals (DAA) therapy in patients with recurrent hepatitis C after liver and kidney transplantation: a cross-sectional study. Front Med, 11 : 1460372.
Czarnecka P,Czarnecka K,Tronina O,Bączkowska T,Wyczałkowska-Tomasik A,Durlik M .2023 .Evaluation of longterm outcomes of direct acting antiviral agents in chronic kidney disease subjects: A single center cohort study. J Clin Med, 12(3513) : 8.
Shaibani B,Ayad K,Melodi M,Albarasi S,Annajar B,Jibani M. .2022 .Outcome of Treatment for Hepatitis C Infection in Hemodialysis Patients with Direct-Acting Second-Generation anti-HCV Drugs at Azzawiyah Kidney Hospital, Libya. Lib J Med Sci, 6 : 53-7.
Rossato G,Tovo CV,Almeida PRL .2020 .Treatment of chronic hepatitis C in patients with chronic kidney disease with Sofosbuvir-basead regimes. Braz J Infect Dis, 24 : 25-9.
Agarwal SK,Bagchi S,Yadav RK .2017 .Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen. Kidney Int Rep, 2 : 831-5.
Bunchorntavakul C,Maneerattanaporn M,Chavalitdhamrong D. .2015 .Management of patients with hepatitis C infection and renal disease. World J Hepatol, 7 : 213-8.
0

Citations

0

Downloads

127

Views